KraneShares Emerging Market Healthcare Index ETF

Download KMED Presentation

Download Fact Sheet

Investment Strategy:

KMED seeks to provide investment results that, before fees and expenses, track the performance of the Solactive Emerging Markets Healthcare Index. The index seeks to track the equity market performance of companies engaged in the health care sector in various emerging markets. The issuers include small-cap, mid-cap, and large-cap companies involved in hospital management, healthcare management, pharmaceutical manufacturing, and biotechnology, among other sub-industries.

Emerging Market Healthcare Sector Highlights:

  • By 2040, emerging market countries on average are projected to increase healthcare spending as percent of GDP by 24.4% compared to just 9.8% in developed markets over the same time period1.
  • In emerging markets, rapid urbanization and rising income is fueling growth in the demand for healthcare services and treatments.
  • Cases of non-communicable diseases (NCDs) such as diabetes and cancer are rising steadily in emerging market countries, presenting a growth opportunity for innovators in the healthcare space.
  • Emerging markets governments are enacting policies such as India’s “National Health Protection Mission” and China’s “Healthy China 2030 Plan” to meet the growing demand for healthcare.

KMED features:

  • Exposure to the Emerging Market healthcare industry with a low correlation to US healthcare equities. Specifically: pharmaceuticals, biotechnology, healthcare administration services, and medical equipment.
  • Access to emerging market innovators in healthcare and pharmaceutical research.
  • Exposure to companies that benefit from the growing and aging EM populations.

1.) Dieleman, Joseph L et al., “Future and potential spending on health 2015–40: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries”, The Lancet , Volume 389 , Issue 10083 , 2005 - 2030.

Fund Details

Data as of 12/03/2021
Primary ExchangeNYSE
Net Assets$2,838,801
Total Annual Fund Operating Expense 0.80%
Inception Date8/29/18
Distribution FrequencyAnnual

Daily Performance

Data as of 12/03/2021
Premium Discount Chart
Net Asset Value$28.39 
Daily Change 0.06%
Market Price $0.00 
Daily Change0.00%
30 Day Median Bid/Ask Spread

The ETF’s 30 Day Median Bid-Ask Spread is calculated by identifying the ETF’s national best bid and national best offer ("NBBO") as of the end of each 10 second interval during each trading day of the last 30 calendar days and dividing the difference between each such bid and offer by the midpoint of the NBBO. The median of those values is identified and that value is expressed as a percentage rounded to the nearest hundredth.

Performance History

Cumulative %
Data as of: 11/30/2021
Fund NAV Closing Price Index
1 Month-1.71% -1.72% -1.95%
3 Month-11.01% -11.01% -11.21%
6 Month-21.04% -21.42% -20.78%
Since Inception16.71% 16.43% 19.64%
Avg Annualized %
Data as of month end: 11/30/2021
Fund NAV Closing PriceIndex
1 Year-11.13% -11.57% -10.60%
3 Year10.46% 10.18% 11.55%
Since Inception4.86% 4.78% 5.66%
Avg Annualized %
Data as of quarter end: 09/30/2021
Fund NAV Closing Price Index
1 Year2.72% 1.16% 3.53%
3 Year8.64% 8.52% 9.74%
Since Inception8.06% 7.87% 8.86%
Growth of $10,000
Data as of 12/03/2021

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted.

The Growth of $10,000 chart reflects an initial investment of $10,000 on the day prior to the selected time period and assumes reinvestment of dividends and capital gains. For the growth of $10,000 chart since inception, the initial investment of $10,000 is instead made on the inception date of the Fund. Fund expenses, including management fees and other expenses were deducted. The growth of a $10,000 investment in the fund is hypothetical and for illustration purposes only.

Top 10 Holdings

Data as of 12/03/2021
Full Holdings .CSV
Rank Name % of Net Assets Ticker Identifier Shares Held Market Value($)
1 SAMSUNG BIOLOGICS CO LTD 4.97% 207940 KR7207940008 185 141,084
2 SUN PHARMACEUTICAL INDUS 4.39% SUNP INE044A01036 12,460 124,619
3 CELLTRION INC 4.20% 068270 KR7068270008 669 119,328
4 SHENZHEN MINDR-A 3.90% 300760 CNE100003G67 2,000 110,702
5 REDE D'OR SAO LUIZ SA 3.31% RDOR3 BRRDORACNOR8 10,800 93,962
6 WUXI BIOLOGICS CAYMAN INC 3.16% 2269 KYG970081173 6,781 89,801
7 DIVI'S LABORATORIES LTD 3.06% DIVI INE361B01024 1,373 86,890
8 SK BIOSCIENCE CO LTD 2.65% 302440 KR7302440003 354 75,140
9 IHH HEALTHCARE BHD 2.43% IHH MYL5225OO007 44,300 68,895
10 BEIGENE LTD 2.02% 6160 KYG1146Y1017 2,100 57,453

Holdings are subject to change.